Cervical cancer remains a critically important problem for women, especially those women in the developing world where the case-fatality rate is high. There are an estimated 528,000 cases and 266,000 deaths worldwide. Established screening and detection programs in the developed world have lowered the mortality from 40/100,000 to 2/100,000 over the last 60 years. The standard of care has been and continues to be: a screening Papanicolaou smear with or without Human Papilloma Virus (HPV) testing; followed by colposcopy and biopsies and if the smear is abnormal; and followed by treatment if the biopsies show high grade disease (cervical intraepithelial neoplasia (CIN) grades 2 and 3 and Carcinoma-in-situ). Low grade lesions (Pap smears with Atypical Cells of Uncertain Significance (ASCUS), Low Grade Squamous Intraepithelial Lesions (LGSIL), biopsies showing HPV changes or showing CIN 1); are usually followed for two years and then treated if persistent. Treatment can be performed with loop excision, LASER, or cryotherapy. Loop excision yields a specimen which can be reviewed to establish the diagnosis more accurately. LASER vaporizes the lesion and cryotherapy leads to tissue destruction. Under long term study; loop excision, LASER, and cryotherapy have the same rate of cure. The standard of care is expensive and takes 6 -12 weeks for the individual patient. During the last twenty years, new technologies that can view the cervix and even image the cervix with cellular resolution have been developed. These technologies could lead to a new paradigm in which diagnosis and treatment occurs at a single visit. These technologies include fluorescence and reflectance spectroscopy (probe or wide-field, whole cervix scanning approaches) and fluorescence confocal endomicroscopy or high resolution micro-endoscopy. 
ren to partake in the vaccine schedule.
Due to the high prevalence rate in women under 30, HPV testing remains a valuable tool for early detection of cervical neoplasia in adults over the age of 30. Researchers found several weaknesses with cytology (Papanicolaou smear) alone: results are dependent on the high quality of the sample being collected; the test requires subjective interpretation of morphological changes within cells, and the prevalence of false negatives. HPV DNA is present in almost all cervical cancers, the tests are readily available and easily performed, and have been found to demonstrate higher sensitivity for high grade CIN (CIN2+) than that achieved by cytology (96.1% vs. 53.0%) [17] . These tests are limited in being used as the primary screening method for cervical cancer because of the lack of specificity. Many patients are identified with infections but both the Papanicolaou smear sampling at colposcopy is negative. Furthermore, because of the high prevalence of HPV DNA before age 30, HPV co-testing is not recommended for women ages 21 to 29. Over the age of 30, past the peak of HPV infections, HPV testing has a higher positive predictive value.
Another limitation of HPV testing, especially in developing countries, is its cost.
According to Mandelblatt et al., the Pap smear costs a mere $10 for the laboratory fee compared to an HPV test at an average laboratory fee of $30 for the hybrid capture II or $77 for PCR [18] . One must also understand that a positive HPV test requires a second visit for either a repeat Pap smear or further diagnosis with colposcopy. Many patients are identified that are HPV positive but their Papanicolaou smear and colposcopically-directed biopsies are negative. The aims of optical technology are to reduce these costs and to provide the patient with a diagnosis and treatment in the same visit. visualizes the changes in chromatin in the cells. Confocal Micro-endoscopy has the resolution to detect cell nuclei. These three changes form the basis for the biological basis for the adoption on new technologies. Table 1 shows endoscope-compatible optical technologies and their role in cancer screening and detection in all organ sites [19] . We know that as intraepithelial neoplasia develops, it secretes growth factors that increase the vasculature to supply nutrients to the lesion. The nuclear-tocytoplasmic ratio increases within cells as less cytoplasm is produced and the amount of DNA within the nucleus increases. Additionally, the stroma underlying Table 2 shows the subjects of this review that pertain to the cervical detection [20] - [105] .
Methods
We searched PubMed and Google scholar from 2007 to 2017 for: fluorescence spectroscopy and screening/detection of cervical neoplasia, and human trials; reflectance spectroscopy and screening/detection of cervical neoplasia, and human trials; fluorescence and reflectance spectroscopy, screening/detection of cervical neoplasia, and human trials; confocal endomicroscopy, fluorescence confocal endomicroscopy, and high resolution Micro Endoscopy, screening/detection of cervical neoplasia, and human trials; optical coherence tomography and screening/detection of cervical neoplasia, and human trials; diffuse optical microscopy and screening/detection of cervical neoplasia, and human trials; and dual mode endomicroscopy and screening/detection of cervical neoplasia, and human 
Overview of the Established Devices

Colposcopy
The colposcopy is a mounted microscope that can enlarge the cervix from 3. 
Multi-Spectral Digital Colposcopy
The multispectral digital colposcope views the cervix in its entirety. Multispectral imaging systems are a modification of the standard colposcope with a video camera adapter that measures reflectance and fluorescence images of the cervix using a color video camera. With two-dimensional imaging, the entire surface of the cervix, including the endocervix, can be visualized, possibly reducing the chance of sampling error. imaging device is built into a handheld wand, which is controlled using custom software that allows for changing the focal depth, recording video and images, basic image corrections, and contrast enhancement. Figure 4 and Figure 5 show how well the device mimics histopathologic sections [172] - [191] . 
Overview of Emerging Technologies
Optical Coherence Tomography (OCT) with or without Autofluorescence Imaging (AFI)
OCT provides high-resolution structural information from below the tissue surface. Analogous to ultrasound but with higher resolution and lower penetration, it allows the clinician to visualize and quantify the thickness of epithelia and detect micro invasion through the basement membrane. 
Diffuse Optical Microscopy (DOM)
Another way of measuring tissue microstructure is to study the tissue's lightscattering properties. Experimental studies suggest that the microscopic and submicroscopic refractive index variations within the cell are the dominant sources of cellular scattering. Owing to the high optical density of the nucleus, cellular light backscattering is mostly influenced by the size of the nucleus and its chromatin texture, allowing detection of dysplasia or cancer-related morphological changes through quantification of tissue light backscattering. In DOM, multiple laterally structured sinusoidal projection patterns are employed to quantify tissue light backscattering. Figure 7 shows the DOM [206] .
Dual Mode Endomicroscopy (DME)
This imaging modality combines fluorescence endomicroscopy (FE) with diffuse optical microscopy (DOM). Combining these two modalities affords complementary sensitivity to the structural changes found in precancerous development. FE images nuclear structure of superficial epithelial cell layers by using a nuclei-staining extrinsic fluorophore dye that reveals dysplasia via increased nuclear size and density. The use of FE alone, however, is limited by its inability to detect moderate dysplasia where structural changes are limited to deeper cell layers. Figure 8 shows the device and images. When FE is combined with DOM, we gain the ability to penetrate tissue to diagnostically meaningful depths within the epithelium. DOM has been described above.
With DME, blue excitation light encounters three major interaction processes relevant to the device: fluorescence, backscattering, and absorption. Acriflavine 
Results of Pilot Studies, Clinical Trials, and Randomized Clinical Trials for Established Technologies
Colposcopy
Mitchell et al. performed a meta-analysis of colposcopy in 1998 and included the largest clinical trials in which patients were referred for abnormal Papanicolaou smears and who presented raw data that could be analyzed. The studies were published in English but came from around the world from recognized coloposcopists. There were 5378 patients for whom raw data was available. The study included the calculation of sensitivities, specificities, positive and negative predictive values, likelihood ratios, and area under the Receiver Operating Curve. In consideration of separating high-grade disease from all other, the weighted sensitivity of colposcopy was 96% and the weighted specificity was 48%.
The ASCUS/LSIL Triage Study for Cervical Cancer (ALTS) trial reported sensitivities for the trial but not specificities. The largest trial which was reported by Cantor and colleagues showed a sensitivity of 100% and a specificity of 71%. In this single study the large data set was divided into training, validation, and testing sets. The code was not broken on the test set until the algorithm was optimized on the training set. The algorithm in this analysis included colposocopic impression. In another analysis when colposcopic impression was eliminated in the algorithm, the sensitivity was 98% and specificity 62%. This study showed that point probe fluorescence and reflectance spectroscopy could be additive to colposcopy by increasing the specificity. That group planned a randomized trial comparing colposcopy to spectroscopy but the study didn't accrue and had to be closed [111] - [133] .
Across all studies, the fluorescence intensity of precancerous lesions is lower than normal squamous tissues, and peak emission wavelength of precancers is shifted to longer emission wavelengths relative to normal tissue (attributed to increased hemoglobin absorption and increased mitochondrial fluorescence in precancers). The performance, however, of optical algorithms is limited by the challenge of discriminating precancers at the junction between squamous and columnar epithelium, where cervical cancers frequently develop. Despite the good performance of this modality, it has not been commercialized. The strongest study is a randomized clinical trial. One has been conducted and reported by Alvarez. The trial evaluated colposcopy versus colposcopy plus the Medispectra LUMA device. The device in the trial showed a sensitivity for the diagnosis of high grade of 56% and a specificity for the diagnosis of High Grade of 87% while for colposcopy the sensitivity was 55% and the specificity was 85%. The device was not additive but was the same as their colposcopy. While the device did not perform with their previously reported high sensitivities (91%, 92%), their colposcopy performance differs from that in the literature. If their colposcopy performance had a sensitivity of 95% then the additional specificity provided by the device would be additive and helpful to decrease unnecessary biopsies [134] - [171] .
Multispectral Digital Colposcopy (MDC) Using Fluorescence and Reflectance Spectroscopy
The LUMA device was approved by the FDA.
Fluorescence Confocal Endomicroscopy
High-resolution techniques such as the confocal can show tissue changes in epithelial cell morphology and architecture without the need for biopsy. Video-rate reflectance confocal microscopy yields images of intact epithelial tissue with 1 -2 micron spatial resolution and with acetic acid, can determine the nuclear to cytoplasmic ratio. Collier showed that the Nuclear to Cytoplasmic (N:C) ratio measured by confocal microscopy could be used to separate high-grade cervical precancers with a sensitivity and specificity greater than 90%. 
Results of Bench Studies, Pilot Studies, and Clinical Trials for Emerging Technologies
Optical Coherence Tomography (OCT)
There are seven published works on OCT in the cervix. Fujimoto described technology and its potential. Zuluaga presented a pilot study and Escobar recruited 50 patients and studied attenuation but did not report sensitivities and specificities.
Wulan and Escobar each reported the use of OCT following the Visual Imaging with Acetic Acid. We acknowledge this is a potential use of the technology that could place it in resource poor settings. This makes the study preselected in a way that is different from those studies in which the only entry is an abnormal Papanicolaou smear.
Liu reported on a large trial in China. There were 1237 participants but this report focuses on the first 299 women for the whom the sensitivity of OCT for the diagnosis of high grade was 24% and the specificity was 96%. Gallwas has two reports, the first from 2010 and the second from 2011. In the first she reports on 60 patients and the sensitivity for the diagnosis of high grade was 95% and the specificity 46%. In the second trial, she reports on 120 women and found that the sensitivity for the diagnosis of high grade was 64% with a specificity of 60%. This is not unusual in the early reporting of a technology.
Future improvements in resolution and the development of new light sources and optics may improve the specificity as well as differentiation of cervical dysplasia. OCT is also being studied for practical use in other gynecologic cancers, including those of the ovaries and fallopian tubes. Our group is combing OCT with autofluorescence imaging [192] - [205] .
Diffuse Optical Microscopy (DOM)
Bodenschatz et al. . In contrast to common endomicroscopic modalities that rely on maximized resolution, DOM makes use of microscopic information encoded in backscattering signals to visualize dysplasia.
The pilot study performed by Bodenschatz et al. suggests that backscattering can be quantified using structured illumination. He studied 18 cervical specimens in which the entire cervical specimen was intact and was measured 30 -90 minutes after excision. The tissue was processed normal and sectioned and read by a gynecologic pathologist. Sensitivities and specificities were not reported.
Low overall costs of the optical setup may make the system ideal for developing countries with the highest incidence of cervical cancer. Also, given its imaging speed and potential for a much larger field of view, DOM may be well suited for large-area tissues screening or for the assessment of resection and tumor margins.
However, the heterogeneity of the cervical epithelium presents a challenge in interpretation of imaging data. Larger imaging fields of views enabled by a wider image guide or a potential noncontact colposcopic or endoscopic implementation may help with the overall differentiation. Image quality may also be improved in the future with enhanced suppression of internal specular reflections using a microscope objective designed for epi-illumination as well as a camera with higher dynamic range. Further studies are needed to confirm the sensitivity of DOM to high nuclear density in cancer [206] .
Dual Mode Endomicroscopy (DME)
We have developed a technology that will soon move to clinical trials in the cervix. Bodenschatz's pilot study with the Dual Mode Endomicroscopy on cervical lesions indicates a strong shift in depth-dependent epithelial backscattering related to the development of cervical precancer. Given the relatively low cost of the DME system, the hope is that after more comprehensive patient studies and acquisition of data, the DME can be used for biopsy guidance and in vivo diagnosis, and possibly also for tumor margin assessment. ability to distinguish HSIL from normal columnar; 38% of the 150 cases associated with the HSIL group had all five observers selecting either "HSIL" or "normal columnar" as their diagnosis [207] .
Conclusions
Here we report on established and emerging technologies relevant to cervical detection. Note that the standard of care paradigm takes not only 6 -12 weeks in the US and Canada but also the full treatment of high grade disease including loop excision pathology bills for ~$5000. The emerging technology arm could be performed in one visit and would cost ~$2000. It may be hard to make the case for change in the developed world. Rogers writes eloquently about diffusion of technologies and the average length for diffusion is 17 years. It has been 18 years since fluorescence and reflectance spectroscopy probe data showed promise, 14 years since multi/hyperspectral colposcopy was successfully reported, and 10 years since a hyperspectral imaging device was FDA approved. It has been 14 years since confocal microendoscopy was reported and 9 since Richards-Kortum put it in a briefcase for the developing world. It's harder to make the case not to use technology in the developing world where resources are not available. We should be ready for translation of both technologies which complement each other nicely in both parts of the world.
OCT has promise and is in clinical trials. OCT has good tissue information but lacks biochemical information. OCT may have more promise if combined measurements of autofluorescence are included. The DOM could complement confocal microendoscopy in the future and maybe less expensive than the current systems under use. Whether it can be placed in a briefcase is left to be seen.
Our hope is that the more established technologies be used and that the emerging ones be tested in large trials to examine clinical effectiveness. Once demonstrated to be effective, they can be scaled to work without electricity in places where cervical cancer runs rampant.
In summary, real-time technologies have the capacity to change screening and diagnosis considerably. The use of these technologies has already been shown to be cost-effective. The impact will be greater, and may extend to the developing world, as the technologies become less expensive to build and simpler to implement [208] - [216] .
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